SANOFI-AVENTIS (EPA:SAN) Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
Directive transparence : information réglementée
20/05/2022 21:15
08/08/2022 21:03
28/07/2022 14:29
20/07/2022 18:52
14/07/2022 07:00
10/07/2022 15:45
10/07/2022 15:45
04/07/2022 12:00
28/06/2022 07:30
28/06/2022 07:30
27/06/2022 22:57